证券代码：301231 证券简称：荣信文化 公告编号：2025-067 荣信教育文化产业发展股份有限公司 第四届董事会第八次会议决议公告 （二）审议通过《关于<2025 年半年度募集资金存放、管理与使用情 况的专项报告>的议案》 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及公司 《募集资金管理制度》等有关规定和要求使用募集资金，不存在违规存放 和使用募集资金的情形。具体内容详见公司同日在巨潮资讯网 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 荣信教育文化产业发展股份有限公司（以下简称"公司"）第四届董 事会第八次会议于 2025 年 8 月 26 日以现场结合通讯表决的方式在公司总 部会议室召开，会议通知于 2025 年 8 月 15 日以书面方式发出。本次会议 由董事长王艺桦女士召集并主持，会议应出席董事 8 人，实际出席董事 8 人，公司高级管理人员列席了会议，会议的召集、召开符合相关法律、行 政法规、部门规章、规范性文件及《荣信教育文化产业发展股份有限公司 章程》 （以下简称"公司章程" ）的有关规定。 二、 ...

Core Viewpoint - Suzhou Nearshore Protein Technology Co., Ltd. plans to use part of its oversubscribed funds amounting to RMB 72 million for permanent working capital, which represents 29.73% of the total oversubscribed funds, pending approval from the shareholders' meeting [1][5]. Fundraising Overview - The company raised a net amount of RMB 1,742.20 million from its initial public offering, with total oversubscribed funds amounting to RMB 242.20 million [2][4]. - The total investment amount for the fundraising projects is RMB 1,500 million, with the planned use of funds from this issuance also being RMB 1,500 million [2]. Plan for Using Oversubscribed Funds - The decision to use RMB 72 million of the oversubscribed funds for working capital is aimed at meeting the company's liquidity needs and improving the efficiency of fund usage, while ensuring that the fundraising projects continue as planned [2][3]. - The company commits that the cumulative use of oversubscribed funds for permanent working capital will not exceed 30% of the total oversubscribed funds within any twelve-month period [3][4]. Review and Approval Process - The board of directors and the supervisory board have approved the proposal to use part of the oversubscribed funds for working capital, which will be submitted for further approval at the shareholders' meeting [5]. - The supervisory board believes that the decision complies with relevant regulations and does not harm the interests of the company or its shareholders, particularly minority shareholders [5].

民生证券股份有限公司关于 苏州近岸蛋白质科技股份有限公司 使用部分超募资金永久补充流动资金的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州 近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发 行股票并在科创板上市的持续督导机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上市公司募集资金监管规则》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律法规 和规范性文件的规定，对近岸蛋白使用部分超募资金永久补充流动资金进行了核 查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2022 年 7 月 25 日出具的《关于同意苏州近岸 蛋白质科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1626 号）批准，公司首次公开发行人民币普通股（A 股）股票（以下简称"本次发行"） 上述募集资金已于 2022 年 9 月 26 日全部到位，容诚会计师事务所（特殊普通合 伙）对公司本次发行的募集资金到位情况进行了审验，并于 2022 年 9 月 26 日出 具了《验资报告》（容诚验字 ...

Core Viewpoint - The company intends to use part of the excess raised funds to permanently supplement its working capital, which is expected to enhance the efficiency of fund utilization and reduce financial costs without affecting the normal progress of investment projects [1][6]. Fundraising Overview - The company was approved to issue 28 million shares at a price of RMB 98.35 per share, raising a total of RMB 2,753.8 million, with a net amount of RMB 2,567.0 million after deducting issuance costs [1]. - The excess funds amount to RMB 186.7 million, with a remaining balance of RMB 13.7 million after repurchasing shares worth RMB 300 million [5]. Fund Management - The company has established a special account for the management of raised funds, which are stored in a dedicated account approved by the board of directors [2]. - A tripartite supervision agreement has been signed with the sponsor and the bank where the special account is held [2]. Previous Use of Excess Funds - The company previously approved the use of excess funds to permanently supplement working capital, with a limit of RMB 50 million, representing 26.78% of the total excess funds [3][4]. Current Plan for Excess Funds - The company plans to use part of the excess funds, not exceeding RMB 23.7 million, which is 12.69% of the total excess funds, for working capital needs [5]. - The company commits that the use of excess funds will not affect the funding requirements of investment projects and will not engage in high-risk investments within twelve months after the fund supplementation [5][6]. Approval Process - The proposal to use part of the excess funds has been approved by the company's board and will be submitted for shareholder approval [6].

Core Viewpoint - Company plans to use part of the raised funds to permanently supplement working capital, which is aimed at improving operational efficiency and reducing financial costs [1][4]. Fundraising Overview - The company raised a total of 578.64 million yuan by issuing 48.56 million shares at a price of 11.90 yuan per share, with a net amount of 507.61 million yuan after deducting fees [2]. Use of Excess Funds - Previously, the company approved the use of 1.72 million yuan of excess funds for permanent working capital, which accounted for 29.10% of the total excess funds [3]. - As of the announcement date, there are 4.89 million yuan of excess funds remaining, including interest income [3]. Current Supplement Plan - The company intends to use 1.77 million yuan of excess funds for permanent working capital, representing 29.94% of the total excess funds, not exceeding 30% [4]. Commitments and Regulations - The company commits that the use of excess funds will only be for main business operations and will not affect the normal progress of investment projects [5]. - The board of directors believes this action is necessary for meeting working capital needs while ensuring compliance with legal regulations [6].

国金证券股份有限公司 关于厦门唯科模塑科技股份有限公司 使用剩余超募资金永久补充流动资金事项的核查意见 国金证券股份有限公司（以下简称"保荐机构"）为厦门唯科模塑科技股份 有限公司（以下简称"唯科科技"或"公司"）首次公开发行股票并在创业板上 市的保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所创 业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》、《上市公司募集资金监管规则》等有关规定，对唯科科 技使用剩余超募资金永久补充流动资金的事项进行了核查，核查情况如下： 一、募集资金基本情况 中国证监会 2021 年 12 月 1 日核发了《关于同意厦门唯科模塑科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2021]3798 号），同意公司首次 公开发行股票的注册申请。根据上述批复，公司公开发行人民币普通股（A 股） 股票 3,120 万股，发行价格为 64.08 元/股，募集资金总额为人民币 1,999,296,000.00 元，扣除与发行有关的费用（不含税）人民币 243,467,806.44 元后，实际募集资 金净额为人民币 1,755 ...

荣旗工业科技(苏州)股份有限公司（证券代码：301360，证券简称：荣旗科技）于2025年8月25日在公 司四楼会议室以现场结合通讯方式召开了第三届董事会第六次会议，会议由董事长钱曙光主持，全体9 名董事均出席了会议，公司监事列席。此次会议审议并通过了多项重要议案。 此外，董事会还通过了《关于提请召开公司2025年第二次临时股东大会的议案》，决定于2025年9月11 日召开临时股东大会，采取现场表决与网络投票相结合的方式，审议相关事项，具体通知已在巨潮资讯 网披露，表决结果为全票同意。 相关备查文件包括第三届董事会第六次会议决议和第三届董事会审计委员会2025年第四次会议决议。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 为了进一步完善公司治理结构，促进公司规范运作，与最新修订的《公司章程》的最新规定保持一致， 结合公司的实际情况，根据《公司法》《上市公司章程指引》《上海证券交易所科创板股票上市规则》 等法律法规和规范性文件的规定，公司制定、修订公司部分内部治理制度，具体制度如下： 除上述条款修改外，《公司章程》其他条款不变。上述变更事项尚需提交公司股东大会审议，并提请股 东大会授权公司管理层根据上述变更办理相关工商登记备案等相关事宜，授权有效期限为自股东大会审 议通过之日起至本次相关工商变更手续及章程备案办理完毕之日止。上述变更最终以工商登记机关核准 的内容为准。 二、修订公司部分管理制度情况 上述修订或制定的公司治理制度已经公司第二届董事会第十六次会议审议通过，部分制度尚需股东大会 审议通过后生效。修订后的《公司章程》及部分治理制度全文详见公司同日披露于上海证券交易所网站 （www.sse.com.cn）的相关文件。 特此公告。 武汉逸飞激光股份有限公司董事会 2025年8月26日 证券代码：688646 证券简称：逸飞激光 公告编号：2025-061 武汉逸飞激光股份 ...

证券代码：688610 证券简称：埃科光电 公告编号：2025-026 合肥埃科光电科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 合肥埃科光电科技股份有限公司（以下简称"公司"）第二届监事会第一次会 议于 2025 年 8 月 25 日在公司会议室以现场方式召开，本次会议通知及相关材料 已于 2025 年 8 月 15 日以通讯方式送达全体监事。会议由监事会主席徐秀云女士 主持，应到监事 3 名，实到监事 3 名，董事会秘书列席了本次会议。会议的召集、 召开及表决程序符合《中华人民共和国公司法》和《公司章程》等相关规定，会 议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事审议，会议以投票表决方式通过如下决议： （一）审议通过《关于 2025 年半年度报告及其摘要的议案》 监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序符合相关 规定，所包含的信息真实客观反映了公司报告期内的财务状况和经营成果。监事 会全体成员保证公司 2025 年半年度报告内容真实、准 ...

Core Viewpoint - The company plans to use remaining raised funds of 212.6831 million yuan to permanently supplement its working capital, which requires approval from the shareholders' meeting [1][5][6]. Fundraising Overview - The company raised a total of 1,858.5324 million yuan from its initial public offering (IPO) by issuing 37.192963 million shares at a price of 49.97 yuan per share, with a net amount after expenses being 1,740.0000 million yuan [1][2]. - The total amount of excess raised funds is 746.2786 million yuan, with the current proposal to use 212.6831 million yuan representing 28.50% of the total excess funds [4][6]. Investment Project Details - The company has allocated 980 million yuan for the construction of a production base for variable frequency drives, servo systems, elevators, and construction hoist system integration [3]. Usage of Remaining Funds - The remaining funds will be used to ensure the efficiency of fund utilization and to lower financial costs while meeting the operational needs of the company [3][5]. - The company commits that the cumulative use of excess funds for working capital will not exceed 30% of the total excess funds within any 12-month period [5][6]. Approval Process - The proposal to use the remaining excess funds was approved in the board and supervisory meetings held on August 22, 2025, and is pending approval from the shareholders' meeting [5][6]. - The sponsor has confirmed that the decision-making process complies with relevant laws and regulations, ensuring that it does not affect the implementation of fundraising projects [6][7].